UPDATED: Alnylam seeks compensation from Moderna and Pfizer in suits over patented delivery of their Covid-19 vaccines
RNAi therapeutics juggernaut Alnylam Pharmaceuticals on Thursday announced that it’s suing and seeking money from both Pfizer and Moderna regarding their use of Alnylam’s biodegradable lipids, which have been integral to the way both companies’ mRNA vaccines work.
The suits, filed in the Delaware district court, both seek “fair compensation for use of its technology” but “no less than a reasonable royalty.” And if successful, the biotech will dip into two of the richest revenue streams the biopharma industry has ever seen.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.